The role of endothelin receptor antagonists in the treatment of chronic heart failure

Current Cardiology Reports

Volumn 3, Issue 3, 2001, Pages 232-240

  Kiowski, Wolfgang ^a   Sütsch, Gabor ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN RECEPTOR;

CHRONIC DISEASE; CONGESTIVE HEART FAILURE; DRUG ANTAGONISM; HUMAN; REVIEW;

CHRONIC DISEASE; HEART FAILURE, CONGESTIVE; HUMANS; RECEPTORS, ENDOTHELIN;

EID: 0035347151     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-001-0028-7     Document Type: Article

References (51)

1. Garg R, Yusuf S: Overview of randomized trials of angiotensin- converting enzyme inhibitors on mortality and morbidity in patients with heart failure: Collaborative Group on ACE Inhibitor Trials. JAMA 1995, 273:1450-1456.
2. Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709-717.
3. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999, 353:2001-2007.
4. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999, 353:9-13.
5. Yanagisawa M, Kurihara H, Kimura S, et al.: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1989, 332:411-415.
6. Kiowski W, Linder L, Stoschitzky K, et al.: Diminished vascular response to inhibition of endothelium-derived nitric oxide and enhanced vasoconstriction to exogenously administered endothelin-1 in clinically healthy smokers. Circulation 1994, 90:27-34.
7. Givertz MM, Colucci WS: New targets for heart-failure therapy: endothelin, inflammatory cytokines, and oxidative stress. Lancet 1998, 352(Suppl 1):SI34-SI38.
8. Clozel M, Breu V, Burri K, et al.: Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature 1993, 365:759-761.
9. Wagner OF, Christ G, Wojta J, et al.: Polar secretion of endothelin- 1 by cultured endothelial cells. J Biol Chem 1992, 267:16066-16068.
10. Hahn AW, Resink TJ, Scott-Burden T, et al.: Stimulation of endothelin mRNA and secretion in rat vascular smooth muscle cells: a novel autocrine function. Cell Regul 1990, 1:649-659.
11. Ito H, Hirata Y, Adachi S, et al.: Endothelin-1 is an autocrine/ paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. J Clin Invest 1993, 92:398-403.
12. Fukunaga M, Fujiwara Y, Ochi S, et al.: Stimulatory effect of thrombin on endothelin-1 production in isolated glomeruli and cultured mesangial cells of rats. J Cardiovasc Pharmacol 1991, 17(Suppl 7):S411-S413.
13. Yanagisawa H, Yanagisawa M, Kapur RP, et al.: Dual genetic pathways of endothelin-mediated intercellular signaling revealed by targeted disruption of endothelin converting enzyme-1 gene. Development 1998, 125:825-836.
14. Wypij DM, Nichols JS, Novak PJ, et al.: Role of mast cell chymase in the extracellular processing of big-endothelin-1 to endothelin-1 in the perfused rat lung. Biochem Pharmacol 1992, 43:845-853.
15. Kido H, Nakano A, Okishima N, et al.: Human chymase, an enzyme forming novel bioactive 31-amino acid length endothelins. Biol Chem 1998, 379:885-891.
16. Fernandez-Patron C, Radomski MW, Davidge ST: Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 1999, 85:906-911.
17. Adachi M, Yang YY, Furuichi Y, Miyamoto C: Cloning and characterization of cDNA encoding human A-type endothelin receptor. Biochem Biophys Res Commun 1991, 180:1265-1272.
18. Nakamuta M, Takayanagi R, Sakai Y, et al.: Cloning and sequence analysis of a cDNA encoding human non-selective type of endothelin receptor. Biochem Biophys Res Commun 1991, 177:34-39.
19. Seo B, Oemar BS, Siebenmann R, et al.: Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation 1994, 89:1203-1208.
20. Love MP, Haynes WG, Webb DJ, McMurray JJ: Venous endothelin receptor function in patients with chronic heart failure. Clin Sci (Colch) 2000, 98:65-70.
21. Takayanagi R, Kitazumi K, Takasaki C, et al.: Presence of non-selective type of endothelin receptor on vascular endothelium and its linkage to vasodilation. Febs Lett 1991, 282:103-106.
22. Rossi GP, Andreis PG, Neri G, et al.: Endothelin-1 stimulates aldosterone synthesis in Conn's adenomas via both A and B receptors coupled with the protein kinase C- and cyclooxygenase- dependent signaling pathways. J Investig Med 2000, 48:343-350.
23. Brooks DP, DePalma PD, Pullen M, et al.: SB 234551, a novel endothelin-A receptor antagonist, unmasks endothelininduced renal vasodilatation in the dog. J Cardiovasc Pharmacol 1998, 31 (Suppl 1):S339-S341.
24. Ponicke K, Vogelsang M, Heinroth M, et al.: Endothelin receptors in the failing and nonfailing human heart. Circulation 1998, 97:744-751.
25. Morawietz H, Szibor M, Goettsch W, et al.: Deloading of the left ventricle by ventricular assist device normalizes increased expression of endothelin ET(A) receptors but not endothelin- converting enzyme-1 in patients with end-stage heart failure. Circulation 2000, 102(19 Suppl 3):III188-III193.
26. Guarda E, Katwa LC, Myers PR, et al.: Effects of endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc Res 1993, 27:2130-2134.
27. Fukuroda T, Fujikawa T, Ozaki S, et al.: Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun 1994, 199:1461-1465.
28. Kiowski W, Luscher TF, Linder L, Buhler FR: Endothelin-1- induced vasoconstriction in humans. Reversal by calcium channel blockade but not by nitrovasodilators or endothelium- derived relaxing factor. Circulation 1991, 83:469-475.
29. Kiowski W, Sütsch G, Hunziker P, et al.: Evidence for endothelin- 1-mediated vasoconstriction in severe chronic heart failure. Lancet 1995, 346:732-736.
30. McClellan G, Weisberg A, Winegrad S: Endothelin regulation of cardiac contractility in absence of added endothelin. Am J Physiol 1995, 268(4 Pt 2):H1621-H1627.
31. Onishi K, Ohno M, Little WC, Cheng CP: Endogenous endothelin- 1 depresses left ventricular systolic and diastolic performance in congestive heart failure. J Pharmacol Exp Ther 1999, 288:1214-1222.
32. MacCarthy PA, Grocott-Mason R, Prendergast BD, Shah AM: Contrasting inotropic effects of endogenous endothelin in the normal and failing human heart: studies with an intracoronary ET(A) receptor antagonist. Circulation 2000, 101:142-147.
33. Cody R, Haas GJ, Binkley PF, et al.: Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992, 85:504-509.
34. Tsutamoto T, Wada A, Maeda Y, et al.: Relation between endothelin- 1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. J Am Coll Cardiol 1994, 23:1427-1433.
35. Stangl K, Dschietzig T, Richter C, et al.: Pulmonary release and coronary and peripheral consumption of big endothelin and endothelin-1 in severe heart failure: acute effects of vasodilator therapy. Circulation 2000, 102:1132-1138.
36. Imai T, Hirata Y, Emori T, et al.: Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells. Hypertension 1992, 19(6 Pt 2):753-757.
37. Jilma B, Krejcy K, Dirnberger E, et al.: Effects of angiotensin-II infusion at pressor and subpressor doses on endothelin-1 plasma levels in healthy men. Life Sci 1997, 60:1859-1866.
38. Parker JD, Thiessen JJ, Reilly R, et al.: Human endothelin-1 clearance kinetics revealed by a radiotracer technique. J Pharmacol Exp Ther 1999, 289:261-265.
39. Tsutamoto T, Wada A, Hisanaga T, et al.: Relationship between endothelin-1 extraction in the peripheral circulation and systemic vascular resistance in patients with severe congestive heart failure. J Am Coll Cardiol 1999, 33:530-537.
40. Krum H, Goldsmith R, Wilshire-Clement M, et al.: Role of endothelin in the exercise intolerance of chronic heart failure. Am J Cardiol 1995, 75:1282-1283.
41. Pacher R, Stanek B, Hülsmann M, et al.: Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 1996, 27:633-641.
42. Pousset F, Isnard R, Lechat P, et al.: Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur Heart J 1997, 18:254-258.
43. Levine TB, Levine AB, Goldberg D, et al.: Impact of medical therapy on pulmonary hypertension in patients with congestive heart failure awaiting cardiac transplantation. Am J Cardiol 1996, 78:440-443.
44. Cowburn PJ, Cleland JG, McArthur JD, et al.: Short-term haemodynamic effects of BQ-123, a selective endothelin ET(A)-receptor antagonist, in chronic heart failure. Lancet 1998, 352:201-202.
45. Spieker LE, Mitrovic V, Noll G, et al.: Acute hemodynamic and neurohumoral effects of selective ET(A) receptor blockade in patients with congestive heart failure: ET 003 Investigators. J Am Coll Cardiol 2000, 35:1745-1752.
46. Dupuis J, Goresky CA, Fournier A: Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors. J Appl Physiol 1996, 81:1510-1515.
47. Sütsch G, Kiowski W, Yan XW, et al.: Short-term oral endothelin- receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 1998, 98:2262-2268.
48. Sütsch G, Bertel O, Rickenbacher P, et al.: Regulation of aldosterone secretion in patients with chronic congestive heart failure by endothelins. Am J Cardiol 2000, 85:973-976.
49. Packer M, Caspi A, Charlon V, et al.: Multicenter, double-blind, placebo-controlled study of long-term endothelin-blockade with bosentan in chronic heart failure- results of the REACH- 1 trial. Circulation 1998, 98(Suppl I):I3.
50. Mulder P, Richard V, Derumeaux G, et al.: Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation 1997, 96:1976-1982.
51. Clozel M, Ramuz H, Clozel JP, et al.: Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use. J Pharmacol Exp Ther 1999, 290:840-846.